



Opana[®] ER (oxymorphone) – Market withdrawal

- On July 6, 2017, [Endo announced](#) the voluntary market withdrawal of [Opana ER \(oxymorphone hydrochloride\)](#) extended-release tablets.
- Endo's announcement follows the FDA's earlier [withdrawal request](#). Based on a review of all available postmarketing data, Opana ER demonstrated a significant shift in the route of abuse from nasal to injection following the product's reformulation.
 - Injection abuse of reformulated Opana ER has been associated with a serious outbreak of human immunodeficiency virus and hepatitis C, as well as cases of thrombotic microangiopathy.
 - However, Endo states that neither the FDA's withdrawal request nor Endo's decision to voluntarily remove Opana ER reflect a finding that the product is unsafe or ineffective when taken as prescribed.
- The FDA's decision to withdraw Opana ER follows a [March 2017 FDA Advisory Committee](#) meeting where a group of independent experts voted 18 – 8 that the benefits of reformulated Opana ER no longer outweighed its risks.
- Opana ER was first approved in 2006 for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting.
- Endo plans to work with the FDA to coordinate the orderly removal of Opana ER in a manner that looks to minimize treatment disruption for patients and allows patients sufficient time to seek guidance from their healthcare professionals.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.